Pfizer has reported positive data for rheumatoid arthritis drug Xeljanz with the publication of two-year results from a major new clinical trial.
Published in the New England Journal of Medicine, the potentially important data from the Oral Start study demonstrated the performance of the drug among more than 950 patients with moderately to severely active rheumatoid arthritis who had not previously received methotrexate.
When taken as a monotherapy, the drug inhibited the progression of structural damage and reduced the signs and symptoms of rheumatoid arthritis. The results proved that Xeljanz was significantly superior to methotrexate on these measures after 24 months.
Dr Steven Romano, global medicines development lead for the Pfizer global innovative pharmaceutical business, said: “The publication of all of the completed Xeljanz phase III rheumatoid arthritis clinical studies in such respected publications speaks of the significance and clinical relevance of the data for Xeljanz.”